199 related articles for article (PubMed ID: 19347234)
1. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic neuroprotection.
De Filippis D; Steardo A; D'Amico A; Scuderi C; Cipriano M; Esposito G; Iuvone T
ScientificWorldJournal; 2009 Mar; 9():229-35. PubMed ID: 19347234
[TBL] [Abstract][Full Text] [Related]
2. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
3. The seek of neuroprotection: introducing cannabinoids.
Martínez-Orgado J; Fernández-López D; Lizasoain I; Romero J
Recent Pat CNS Drug Discov; 2007 Jun; 2(2):131-9. PubMed ID: 18221224
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists.
Talwar R; Potluri VK
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):536-44. PubMed ID: 21631407
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological actions of cannabinoids.
Pertwee RG
Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures.
Kreutz S; Koch M; Ghadban C; Korf HW; Dehghani F
Exp Neurol; 2007 Jan; 203(1):246-57. PubMed ID: 17010339
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid mechanisms of pain suppression.
Walker JM; Hohmann AG
Handb Exp Pharmacol; 2005; (168):509-54. PubMed ID: 16596786
[TBL] [Abstract][Full Text] [Related]
8. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
9. Microglial Cannabinoid CB
Xu K; Wu Y; Tian Z; Xu Y; Wu C; Wang Z
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768668
[TBL] [Abstract][Full Text] [Related]
10. Targeting the cannabinoid system for pain relief?
Chiou LC; Hu SS; Ho YC
Acta Anaesthesiol Taiwan; 2013 Dec; 51(4):161-70. PubMed ID: 24529672
[TBL] [Abstract][Full Text] [Related]
11. The endocannabinoid system in amyotrophic lateral sclerosis.
Bilsland LG; Greensmith L
Curr Pharm Des; 2008; 14(23):2306-16. PubMed ID: 18781981
[TBL] [Abstract][Full Text] [Related]
12. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
De Petrocellis L; Di Marzo V
J Neuroimmune Pharmacol; 2010 Mar; 5(1):103-21. PubMed ID: 19847654
[TBL] [Abstract][Full Text] [Related]
13. Prospects for cannabinoid therapies in viral encephalitis.
Solbrig MV; Fan Y; Hazelton P
Brain Res; 2013 Nov; 1537():273-82. PubMed ID: 24021420
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.
Croxford JL; Pryce G; Jackson SJ; Ledent C; Giovannoni G; Pertwee RG; Yamamura T; Baker D
J Neuroimmunol; 2008 Jan; 193(1-2):120-9. PubMed ID: 18037503
[TBL] [Abstract][Full Text] [Related]
15. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
16. Synthetic cannabinoids: analysis and metabolites.
Elsohly MA; Gul W; Wanas AS; Radwan MM
Life Sci; 2014 Feb; 97(1):78-90. PubMed ID: 24412391
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit.
Ganon-Elazar E; Akirav I
Psychoneuroendocrinology; 2013 Sep; 38(9):1675-87. PubMed ID: 23433741
[TBL] [Abstract][Full Text] [Related]
18. The multiplicity of action of cannabinoids: implications for treating neurodegeneration.
Gowran A; Noonan J; Campbell VA
CNS Neurosci Ther; 2011 Dec; 17(6):637-44. PubMed ID: 20875047
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2.
Arévalo-Martín A; García-Ovejero D; Rubio-Araiz A; Gómez O; Molina-Holgado F; Molina-Holgado E
Eur J Neurosci; 2007 Sep; 26(6):1548-59. PubMed ID: 17880390
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance.
Cabral GA; Marciano-Cabral F
J Leukoc Biol; 2005 Dec; 78(6):1192-7. PubMed ID: 16204639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
